HuoXue JieDu formula improves diabetic retinopathy in rats by regulating microRNAs

Liu, Hongli; Hao, Guiyang; Tang, Shijie; Sun, Hongtao; Fang, Yongsheng; Pang, Xinxin; Liu, Hanying; Ji, Qingxuan; Wang, Xirui; Tian, Jingyun; Jiang, Kunxiu; Song, Xingzhuo; Zhu, Rong; Han, Jing; Wang, Wei

doi:10.1016/j.jep.2020.113616

Cited by 13 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For these reasons, this model is widely used to study diabetes and its complications, including DR. A previous report using this model found that STZ signi cantly reduced blood insulin levels and increased oxidation and in ammation levels throughout the body including the eyes. In addition, the retinal structure of DM rats was seriously damaged, and the number of RGCs was reduced by about one-third [33] .…”

Section: Discussionmentioning

confidence: 99%

TBHQ Regulates the Nrf2/HO-1 Pathway to Enhance Stem Cell Treatment of Diabetic Retinopathy

Xu¹,

Tian²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: To investigate the therapeutic effect of human umbilical cord mesenchymal stem cells (hUCMSCs) on diabetic retinopathy (DR) in diabetic rats, and to study the mechanism of hUCMSCs in treating diabetic retinopathy by tert-butylhydroquinone (tBHQ) regulation of the Nrf2/HO-1 pathway.Methods: The diabetic rat model was induced by intraperitoneal injection of streptozotocin (STZ). The experimental animals were divided into six groups: Normal, diabetes mellitus (DM), hUCMSCs, tBHQ, combined tBHQ-hUCMSCs, and all-trans-retinoid acid (ATRA)-hUCMSCs combined group. Visual function experiments and histological analyses were performed eight weeks post intravitreal injection. Biochemical and molecular analyses were used to assess the hUCMSCs composition and its biological effects.Results: Improvements in systemic oxidative stress and inflammation were found in the tBHQ group. Although hUCMSCs had no significant effect on oxidative stress, retinal structure was improved, visual defects reduced and expression of local retinal inflammatory factors were inhibited following its application. The effect of combined therapy was better than that of single therapy. Inhibition of the Nrf2/HO-1 pathway can promote the expression of systemic inflammatory factors and inhibit the therapeutic effect of hUCMSCs in the retina.Conclusions: Intravitreal administration of hUCMSCs triggers an effective cytoprotective microenvironment in the retina of diabetic mice. Alone, however, it may not significantly improve the systemic inflammatory response of diabetes. In combination with tBHQ it may promote Nrf2expression, systemic antioxidant stress and therapeutic effects of hUCMSCs.

show abstract

Section: Discussionmentioning

confidence: 99%

TBHQ Regulates the Nrf2/HO-1 Pathway to Enhance Stem Cell Treatment of Diabetic Retinopathy

Xu¹,

Tian²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Additionally, the mechanisms of the Huo-Xue-Jie-Du Formula (HXJDF) involved regulating microRNA levels (e.g., miR-423-5p, miR-341, miR-3562, miR-3588, miR-500-3p, miR-3099) to restore RGC numbers and inhibit retinal cell apoptosis (Li et al. 2021 ).…”

Section: Methodsmentioning

confidence: 99%

Clinical observations and mechanistic insights of traditional Chinese medicine in the management of diabetic retinopathy

Chen,

Ni,

Yao

et al. 2024

Pharmaceutical Biology

View full text Add to dashboard Cite

“…The HuoXue JieDu formula is a classical formula that restores the retinal thickness and RGC number and decreases retinal cell apoptosis by regulating 15 miRNAs [ 138 ]; these miRNAs may be potential therapeutic targets for DR.…”

Section: Drug Regulationmentioning

confidence: 99%

Noncoding RNAs Are Promising Therapeutic Targets for Diabetic Retinopathy: An Updated Review (2017–2022)

Wang

Jin

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is the most common complication of diabetes. It is also the main cause of blindness caused by multicellular damage involving retinal endothelial cells, ganglial cells, and pigment epithelial cells in adults worldwide. Currently available drugs for DR do not meet the clinical needs; thus, new therapeutic targets are warranted. Noncoding RNAs (ncRNAs), a new type of biomarkers, have attracted increased attention in recent years owing to their crucial role in the occurrence and development of DR. NcRNAs mainly include microRNAs, long noncoding RNAs, and circular RNAs, all of which regulate gene and protein expression, as well as multiple biological processes in DR. NcRNAs, can regulate the damage caused by various retinal cells; abnormal changes in the aqueous humor, exosomes, blood, tears, and the formation of new blood vessels. This study reviews the different sources of the three ncRNAs—microRNAs, long noncoding RNAs, and circular RNAs—involved in the pathogenesis of DR and the related drug development progress. Overall, this review improves our understanding of the role of ncRNAs in various retinal cells and offers therapeutic directions and targets for DR treatment.

show abstract

HuoXue JieDu formula improves diabetic retinopathy in rats by regulating microRNAs

Cited by 13 publications

References 47 publications

TBHQ Regulates the Nrf2/HO-1 Pathway to Enhance Stem Cell Treatment of Diabetic Retinopathy

TBHQ Regulates the Nrf2/HO-1 Pathway to Enhance Stem Cell Treatment of Diabetic Retinopathy

Clinical observations and mechanistic insights of traditional Chinese medicine in the management of diabetic retinopathy

Noncoding RNAs Are Promising Therapeutic Targets for Diabetic Retinopathy: An Updated Review (2017–2022)

Contact Info

Product

Resources

About